Neoadjuvant rh-endostatin, docetaxel, and epirubicin for breast cancer: Efficacy and safety in a prospective, randomized, phase II study.

L Wang,J Wang,T Wang,Q Yao,H Wang,J Chen,Y Huan,X Zhou,J Zhang

doi:10.1200/jco.2011.29.15_suppl.1132

Abstract

1132 Background: Rh-endostatin, a protein modified by an additional nine-amino acid sequence to the N-terminal of endostatin, is a novel antiangiogenesis drug developed in China. Previous data sugg...

Highlights

Recombinant human endostatin is a novel antiangiogenesis drug developed in China
Antiangiogenic therapy for cancer has attracted considerable attention. The rationale behind it is that tumor growth is dependent on angiogenesis [2], which was proposed by Dr Folkman and has been confirmed by basic and clinical research
Rh-endostatin increased tumor response rate, and significantly improved the overall survival (OS) without increasing the adverse effects. In another multicenter, randomized, double-blind, placebo-controlled study published in 2011, treatment with paclitaxel and carboplatin (TC) plus rhendostatin improved objective response rate (ORR) in patients with advanced non-small cell lung cancer (NSCLC) and exhibited a good safety profile, the differences in progression free survival (PFS) or OS were not statistically significant from Paclitaxel and carboplatin (TC) alone [6]. All these findings suggest that rh-endostatin may be effective as well in the treatment of other solid tumors, including breast cancer

Summary

Introduction

Recombinant human endostatin (rh-endostatin) is a novel antiangiogenesis drug developed in China. Antiangiogenic therapy for cancer has attracted considerable attention. The rationale behind it is that tumor growth is dependent on angiogenesis [2], which was proposed by Dr Folkman and has been confirmed by basic and clinical research. Endostatin can directly target capillary endothelial cells around the tumor without detectable toxicity in normal cells. It may inhibit cell migration, induce cell apoptosis, and play a multitargeted antiangiogenic role by regulating expression of vascular endothelial growth factor (VEGF) and activity of proteolytic enzymes, indirectly leading to the quiescence or reduction of tumors [4]

Methods

Results

Discussion

Conclusion